poisar

Stocks · News reference

Silexion Therapeutics shares are trading lower. The company announced that the first patient worldwide has been dosed in its Phase 2/3 clinical trial evaluating lead candidate, SIL204, in patients with locally advanced pancreatic cancer.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SLXN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Silexion Therapeutics Corp.

    Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

    Silexion Therapeutics announced the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204, an RNAi therapy for locally advanced pancreatic cancer with KRAS mutations. The trial combines direct intratumoral EUS-guided delivery with subcutaneous dosing alongside standard chemotherapy. The study includes an initial safety cohort of ~18 patients followed by expansion to ~166 patients across Israel and Germany.

    SLXNSLXNW